
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen's financial outlook appears robust due to substantial sales growth from its flagship product Tavneos, which saw a remarkable 81% increase in the fourth quarter of 2024, contributing to overall U.S. sales of approximately $716 million in 2022, following a label expansion. The acquisition of Horizon Therapeutics has strengthened the company’s portfolio by adding several rare-disease treatments, including Tepezza, further enhancing its growth prospects alongside a strong emerging pipeline that includes promising candidates like Olpasiran and Imdelltra. Moreover, Amgen's strong cash position, coupled with a well-diversified product portfolio across key therapeutic areas, supports sustained long-term growth potential and reinforces the company's status as a high-quality player in the biotechnology sector.
Bears say
Amgen faces significant risks that may negatively impact its financial outlook, primarily due to heightened competition within its core business franchise, which could lead to market share erosion and increased pricing pressure. Additionally, the company is experiencing challenges related to lower-than-expected uptake for its newer products and potential regulatory setbacks for its late-stage pipeline and biosimilars. Looking ahead, management anticipates a potential mid-single-digit decline in pricing for its cholesterol-lowering drug, Repatha, which may further strain revenue growth as the competitive landscape evolves.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares